571 related articles for article (PubMed ID: 18348593)
1. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
2. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
3. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
5. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
7. Switching antipsychotic medications: not enough, too often, or just right?
Weiden PJ
Am J Psychiatry; 2011 Sep; 168(9):882-4. PubMed ID: 21890800
[No Abstract] [Full Text] [Related]
8. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
[TBL] [Abstract][Full Text] [Related]
9. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.
Bushe CJ; Leonard BE
J Clin Psychiatry; 2007 Nov; 68(11):1682-90. PubMed ID: 18052561
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
[TBL] [Abstract][Full Text] [Related]
13. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Olfson M; Gerhard T; Huang C; Lieberman JA; Bobo WV; Crystal S
Schizophr Bull; 2012 Jun; 38(4):845-53. PubMed ID: 21307041
[TBL] [Abstract][Full Text] [Related]
15. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Moons T; Claes S; Martens GJ; Peuskens J; Van Loo KM; Van Schijndel JE; De Hert M; van Winkel R
Schizophr Res; 2011 Feb; 125(2-3):187-93. PubMed ID: 21050724
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics for the treatment of disruptive behavior.
Lohr WD; Honaker J
Pediatr Ann; 2013 Feb; 42(2):72-7. PubMed ID: 23379410
[No Abstract] [Full Text] [Related]
17. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Citrome L; Volavka J
Postgrad Med; 2004 Oct; 116(4):49-51, 55-9, 63. PubMed ID: 15510593
[TBL] [Abstract][Full Text] [Related]
18. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
Wang PS; Schneeweiss S; Setoguchi S; Patrick A; Avorn J; Mogun H; Choudhry NK; Brookhart MA
J Clin Psychopharmacol; 2007 Dec; 27(6):707-10. PubMed ID: 18004143
[No Abstract] [Full Text] [Related]
19. Metabolic effects of the atypical antipsychotics.
Wooten J
South Med J; 2007 Aug; 100(8):771-2. PubMed ID: 17713300
[No Abstract] [Full Text] [Related]
20. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
L'Italien GJ; Casey DE; Kan HJ; Carson WH; Marcus RN
J Clin Psychiatry; 2007 Oct; 68(10):1510-6. PubMed ID: 17960964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
